Clinical status of capecitabine in the treatment of breast cancer

William J. Gradishar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


New treatment strategies for advanced breast cancer have focused on both the development of new molecular targets in breast cancer cells, as well as improving the therapeutic index of presently available therapy. The development of capecitabine (Xeloda), a new oral fluoropyrimidine, is an example of a chemotherapy drug that has single-agent activity in heavily pretreated patients with advanced breast cancer, with the added convenience of good oral bioavailability. Capecitabine is an excellent treatment option for patients who require symptom palliation and who prefer oral medications. The discussion that follows reviews the clinical data on the use of capecitabine in advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)69-72
Number of pages4
Issue number1 SUPPL. 2
StatePublished - 2001

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical status of capecitabine in the treatment of breast cancer'. Together they form a unique fingerprint.

Cite this